Companies / BOC Sciences / Tislelizumab
BOC Sciences

Tislelizumab | BOC Sciences

Tislelizumab is a humanized monoclonal antibody (MAb) that targets PD-1 to prevent it binding to PD-L1 and PD-L2. Tislelizumab is developed for the treatment of solid tumor.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.